Karin Hygge Blakeman

871 total citations
24 papers, 697 citations indexed

About

Karin Hygge Blakeman is a scholar working on Physiology, Cellular and Molecular Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Karin Hygge Blakeman has authored 24 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 9 papers in Cellular and Molecular Neuroscience and 8 papers in Psychiatry and Mental health. Recurrent topics in Karin Hygge Blakeman's work include Pain Mechanisms and Treatments (8 papers), Migraine and Headache Studies (7 papers) and Neuropeptides and Animal Physiology (7 papers). Karin Hygge Blakeman is often cited by papers focused on Pain Mechanisms and Treatments (8 papers), Migraine and Headache Studies (7 papers) and Neuropeptides and Animal Physiology (7 papers). Karin Hygge Blakeman collaborates with scholars based in Sweden, United States and United Kingdom. Karin Hygge Blakeman's co-authors include Zsuzsanna Wiesenfeld‐Hallin, Martha M. Faraday, Neil E. Grunberg, Jan M. Mathé, Xiao‐Jun Xu, George G. Nomikos, Jacqueline N. Crawley, Tomas Hökfelt, Philippe Naveilhan and Patrik Ernfors and has published in prestigious journals such as Nature, Neurology and Brain Research.

In The Last Decade

Karin Hygge Blakeman

21 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karin Hygge Blakeman Sweden 12 449 267 261 79 71 24 697
Michelle Vincler United States 18 403 0.9× 412 1.5× 671 2.6× 75 0.9× 58 0.8× 24 1.1k
V. Fardin France 15 565 1.3× 390 1.5× 335 1.3× 39 0.5× 75 1.1× 26 775
Mayumi Nakajima Japan 16 484 1.1× 470 1.8× 334 1.3× 47 0.6× 20 0.3× 45 999
Michael J. Piesla United States 7 289 0.6× 120 0.4× 153 0.6× 59 0.7× 37 0.5× 7 648
Margit Szikszay Hungary 16 460 1.0× 391 1.5× 348 1.3× 102 1.3× 38 0.5× 39 811
Emilie Laboureyras France 12 266 0.6× 286 1.1× 191 0.7× 105 1.3× 43 0.6× 18 614
W.A. Prado Brazil 18 345 0.8× 527 2.0× 293 1.1× 175 2.2× 40 0.6× 48 1.1k
Akihiko Yonezawa Japan 15 343 0.8× 326 1.2× 258 1.0× 31 0.4× 27 0.4× 62 730
P L van Giersbergen Netherlands 7 437 1.0× 95 0.4× 246 0.9× 28 0.4× 180 2.5× 9 671

Countries citing papers authored by Karin Hygge Blakeman

Since Specialization
Citations

This map shows the geographic impact of Karin Hygge Blakeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Hygge Blakeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Hygge Blakeman more than expected).

Fields of papers citing papers by Karin Hygge Blakeman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Hygge Blakeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Hygge Blakeman. The network helps show where Karin Hygge Blakeman may publish in the future.

Co-authorship network of co-authors of Karin Hygge Blakeman

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Hygge Blakeman. A scholar is included among the top collaborators of Karin Hygge Blakeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Hygge Blakeman. Karin Hygge Blakeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Terwindt, Gisela M., Jessica Ailani, Lucy Abraham, et al.. (2025). Underdiagnosis and impact of menstrual migraine in real‐world clinical practice: A real‐world survey. Headache The Journal of Head and Face Pain. 65(8). 1413–1427.
2.
Rosen, Noah, et al.. (2025). Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States. Headache The Journal of Head and Face Pain.
3.
Coppola, Gianluca, et al.. (2025). The epidemiology and unmet need of migraine in five european countries: results from the national health and wellness survey. BMC Public Health. 25(1). 254–254. 2 indexed citations
4.
5.
Lipton, Richard B., Astrid Gendolla, Lucy Abraham, et al.. (2024). Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review. Headache The Journal of Head and Face Pain. 65(1). 164–179. 3 indexed citations
6.
Ailani, Jessica, Feng Dai, Aaron Jenkins, et al.. (2024). Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study. Current Medical Research and Opinion. 40(11). 1913–1920. 1 indexed citations
7.
8.
Heilig, Markus, et al.. (2023). Problematic opioid use among osteoarthritis patients with chronic post-operative pain after joint replacement: analyses from the BISCUITS study. Scandinavian Journal of Pain. 23(2). 353–363. 5 indexed citations
9.
Arendt‐Nielsen, Lars, et al.. (2022). Prescription patterns and predictors of unmet pain relief in patients with difficult-to-treat osteoarthritis in the Nordics: analyses from the BISCUITS study. Scandinavian Journal of Pain. 23(1). 149–160. 3 indexed citations
10.
Sandberg, Lars, Ulrika Yngve, Tjerk Bueters, et al.. (2012). 3-Oxoisoindoline-1-carboxamides: Potent, State-Dependent Blockers of Voltage-Gated Sodium Channel NaV1.7 with Efficacy in Rat Pain Models. Journal of Medicinal Chemistry. 55(15). 6866–6880. 55 indexed citations
11.
Brumovsky, Pablo R., Karin Hygge Blakeman, Marcelo J. Villar, et al.. (2006). Phenotyping of sensory and sympathetic ganglion neurons of a galanin-overexpressing mouse—Possible implications for pain processing. Journal of Chemical Neuroanatomy. 31(4). 243–262. 25 indexed citations
12.
Faraday, Martha M., Karin Hygge Blakeman, & Neil E. Grunberg. (2005). Strain and sex alter effects of stress and nicotine on feeding, body weight, and HPA axis hormones. Pharmacology Biochemistry and Behavior. 80(4). 577–589. 63 indexed citations
13.
Blakeman, Karin Hygge, Pablo R. Brumovsky, Jing‐Xia Hao, et al.. (2004). Galanin over-expression decreases the development of neuropathic pain-like behaviors in mice after partial sciatic nerve injury. Brain Research. 1025(1-2). 152–158. 36 indexed citations
14.
Crawley, Jacqueline N., Elliott J. Mufson, John G. Hohmann, et al.. (2002). Galanin overexpressing transgenic mice. Neuropeptides. 36(2-3). 145–156. 46 indexed citations
15.
Naveilhan, Philippe, Hessameh Hassani, Guilherme Lucas, et al.. (2001). Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature. 409(6819). 513–517. 154 indexed citations
16.
Blakeman, Karin Hygge, Kristina Holmberg, Jing‐Xia Hao, et al.. (2001). Mice over-expressing galanin have elevated heat nociceptive threshold. Neuroreport. 12(2). 423–425. 36 indexed citations
17.
Hao, Jing‐Xia, Karin Hygge Blakeman, Wei Yu, et al.. (2000). Development of a Mouse Model of Neuropathic Pain Following Photochemically Induced Ischemia in the Sciatic Nerve. Experimental Neurology. 163(1). 231–238. 43 indexed citations
18.
19.
Mathé, Jan M., et al.. (1999). Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology. 38(1). 121–128. 80 indexed citations
20.
Blakeman, Karin Hygge, Andrej Weintraub, & Göran Widmalm. (1998). Structural determination of the O‐antigenic polysaccharide from the enterotoxigenic Escherichia coli O147. European Journal of Biochemistry. 251(1-2). 534–537. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle Vincler Breakdown of academic impact, for papers by V. Fardin Breakdown of academic impact, for papers by Mayumi Nakajima Breakdown of academic impact, for papers by Michael J. Piesla Breakdown of academic impact, for papers by Margit Szikszay Breakdown of academic impact, for papers by Emilie Laboureyras Breakdown of academic impact, for papers by W.A. Prado Breakdown of academic impact, for papers by Akihiko Yonezawa Breakdown of academic impact, for papers by P L van Giersbergen
Rankless by CCL
2026